Doncaster and Bassetlaw Teaching Hospitals (DBTH) has become the first site in Europe to enrol patients in a revolutionary clinical study evaluating the efficacy and safety of Ravulizumab, a potential treatment for Immunoglobulin A Nephropathy (IgAN).